Capital Group leads Series E for China’s Innovent Biologics
Capital Group Private Markets (CGPM), a private equity affiliate of US-based Capital Group Companies, has led a $150 million Series E round for Chinese biopharmaceutical developer Innovent Biologics.
This is the first investment in Innovent by CGPM, which focuses on emerging markets companies in the healthcare, consumer and business services sectors. Other new investors in the round include Ally Bridge,...
More on Greater China
Latest News
Bertelsmann to invest $500m in India
Bertelsmann India Investments has earmarked USD 500m, provided by its eponymous German parent, for investment in local start-ups. The VC unit’s total deployment since its launch in 2013 is USD 285m.
Entrepreneur First raises $158m, targets SE Asia
UK-headquartered incubator Entrepreneur First (EF) has raised USD 158m, targeted in part at investment in Southeast Asian start-ups and expanding its reach in the region.
CDH exits New Zealand supplements brand to Nestle
CDH Investments has agreed to sell New Zealand-based supplements manufacturer The Better Health Company (TBHC) to Nestlé Health Science for an undisclosed sum.
Panthera hits first close on India, Southeast Asia fund
India and Southeast Asia-focused Panthera Growth Partners has reached a first close on its second fund with commitments amounting to more than half the overall target of USD 250m.